Integrated Filing — IndAS



General information about company

Scrip Code 543427
NSE Symbol MEDPLUS
MSEI Symbol NOTLISTED
ISIN INE804L01022
Name of company Medplus Health Services Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 30-01-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 03-01-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 30-01-2026   14:30:00
End date and time of board meeting 30-01-2026   16:45:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 1,80,611.80 5,02,808.10
Other income 1,824.10 5,072.90
Total income 1,82,435.90 5,07,881.00
2 Expenses
(a) Cost of materials consumed 2,051.90 6,310.50
(b) Purchases of stock-in-trade 1,36,150.30 3,63,534.90
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (4,834.60) 1,520.90
(d) Employee benefit expense 23,264.80 64,641.10
(e) Finance costs 3,082.90 8,701.30
(f) Depreciation, depletion and amortisation expense 7,274.10 20,692.10
(f) Other Expenses
1 Other Expenses 8,117.80 22,981.40
Total other expenses 8,117.80 22,981.40
Total expenses 1,75,107.20 4,88,382.20
3 Total profit before exceptional items and tax 7,328.70 19,498.80
4 Exceptional items 0.00 0.00
5 Total profit before tax 7,328.70 19,498.80
6 Tax expense
7 Current tax 2,065.00 5,527.20
8 Deferred tax (515.10) (1,591.70)
9 Total tax expenses 1,549.90 3,935.50
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 5,778.80 15,563.30
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 5,778.80 15,563.30
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period 5,778.80 15,563.30
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 5,780.70 15,566.60
Total profit or loss, attributable to non-controlling interests (1.90) (3.30)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 5,780.70 15,566.60
Total comprehensive income for the period attributable to owners of parent non-controlling interests (1.90) (3.30)
21 Details of equity share capital
Paid-up equity share capital 2,396.40 2,396.40
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.82 12.99
Diluted earnings (loss) per share from continuing operations 4.81 12.96
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.82 12.99
Diluted earnings (loss) per share from continuing and discontinued operations 4.81 12.96
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1.The above unaudited consolidated financial results of MedPlus Health Services Limited ('the Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“listing regulations”) from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on January 30, 2026. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same. 2.During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from December 23, 2021. The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below: (Rs. In Millions) Objects as per Prospectus Planned utilisation as per Prospectus Utilisation up to December 31, 2025 Unutilised amount as on December 31, 2025* i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements 4,671.70 4,671.70 - ii) General Corporate Purposes 1,117.63 1,095.13 22.50 Total 5,789.33 5,766.83 22.50 * The aforesaid unutilised proceeds of Rs. 22.50 million have been placed as fixed deposits with bank. 3.On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and recorded the incremental impact of these changes amounting to INR 70.59 million as employee benefits expense. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 4.The earnings per equity share for the quarters and nine months ended are not annualised. 5.The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com. For and on behalf of the Board of Directors of MedPlus Health Services Limited G. Madhukar Reddy Managing Director and Chief Executive Officer DIN: 00098097 Place: Hyderabad Date: January 30, 2026



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 a. Retail 1,77,337.00 4,93,113.00
2 b. Diagnostics Services 3,266.70 9,620.70
3 c. Others 0.000081 0.000744
Total Segment Revenue 1,80,611.80 5,02,808.10
Less: Inter segment revenue 0.00 0.00
Revenue from operations 1,80,611.80 5,02,808.10
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 a. Retail 6,413.00 16,828.80
2 b. Diagnostics Services 49.20 77.60
3 c. Others (17.30) 24.30
Total Profit before tax 6,444.90 16,930.70
i. Finance cost 1.80 2.90
ii. Other Unallocable Expenditure net off Unallocable income (885.60) (2,571.00)
Profit before tax 7,328.70 19,498.80
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 a. Retail 2,90,153.60 2,90,153.60
2 b. Diagnostics Services 14,331.50 14,331.50
3 c. Others 68.00 68.00
Total Segment Asset 3,04,553.10 3,04,553.10
Un-allocable Assets 68,284.70 68,284.70
Net Segment Asset 3,72,837.80 3,72,837.80
4 Segment Liabilities
Segment Liabilities
1 a. Retail 1,72,225.70 1,72,225.70
2 b. Diagnostics Services 10,310.20 10,310.20
3 c. Others 16.90 16.90
Total Segment Liabilities 1,82,552.80 1,82,552.80
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 1,82,552.80 1,82,552.80
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 0.00 0.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 B S R and Co Yes 30-04-2026